Biomerieux SA
F:EYW

Watchlist Manager
Biomerieux SA Logo
Biomerieux SA
F:EYW
Watchlist
Price: 206.421 EUR 199.02% Market Closed
Market Cap: €10.8B

Wall St Price Targets

EYW Price Targets Summary
Biomerieux SA

Wall Street analysts forecast EYW stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EYW is 235.468 EUR with a low forecast of 186.096 EUR and a high forecast of 302.29 EUR.

Lowest Forecast
Price Target
186.096 EUR
10% Downside
Average Forecast
Price Target
235.468 EUR
14% Upside
Highest Forecast
Price Target
302.29 EUR
46% Upside
Biomerieux SA Competitors:
Price Targets
RVSB
Riverview Bancorp Inc
36% Upside
558
LK Technology Holdings Ltd
126% Upside
PAT
Panthera Resources PLC
275% Upside
GRTX
Galera Therapeutics Inc
166% Upside
ZIP
Ziprecruiter Inc
20% Upside

Revenue
Forecast

8% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss
8% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 8%. The projected CAGR for the next 5 years is 5%.

Gross Profit
Forecast

8% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
8% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 8%. The projected CAGR for the next 5 years is 5%.

Operating Income
Forecast

7% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
7% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 7%. The projected CAGR for the next 5 years is 8%.

Pre-Tax Income
Forecast

7% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss
7% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 7%. The projected CAGR for the next 3 years is 15%.

Net Income
Forecast

9% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
9% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been 9%. The projected CAGR for the next 5 years is 14%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is EYW's stock price target?
Price Target
235.468 EUR

According to Wall Street analysts, the average 1-year price target for EYW is 235.468 EUR with a low forecast of 186.096 EUR and a high forecast of 302.29 EUR.

What is the Revenue forecast for Biomerieux SA?
Projected CAGR
5%

Over the last 13 years, the compound annual growth rate for Revenue has been 8%. The projected CAGR for the next 5 years is 5%.

What is the Gross Profit forecast for Biomerieux SA?
Projected CAGR
5%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 8%. The projected CAGR for the next 5 years is 5%.

What is the Operating Income forecast for Biomerieux SA?
Projected CAGR
8%

Over the last 13 years, the compound annual growth rate for Operating Income has been 7%. The projected CAGR for the next 5 years is 8%.

What is the Pre-Tax Income forecast for Biomerieux SA?
Projected CAGR
15%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 7%. The projected CAGR for the next 3 years is 15%.

What is the Net Income forecast for Biomerieux SA?
Projected CAGR
14%

Over the last 13 years, the compound annual growth rate for Net Income has been 9%. The projected CAGR for the next 5 years is 14%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett